Pharmaceutical Brand Strategy

We build the brands
clinicians trust
and patients reach for.

From molecule diagrams reimagined as brand marks to packaging systems that make a pill bottle feel like a promise.

47+Brands launched
12FDA approvals supported
3.2×Avg. recall lift
Scroll
Act I — The Problem

Every pharma brand looks
exactly the same.

The same blue shield. The same geometric sans-serif. The same forgettable packaging that disappears the moment a clinician turns away. Generic doesn't just describe the drug — it describes the brand.

CARDIOMAX

Trusted by doctors

NEUROZEN

Advanced formula

IMMUNEX

Clinically proven

VITAPLEX

For better health

ONCOVIR

Precision medicine

RESPIREX

Breathe easy

OSTEOCARE

Strong bones

DERMATEK

Skin science

GLYCOBAL

Balance restored

NEPHROMAX

Kidney health

HEPACARE

Liver support

THROMBO

Blood flow

"Sameness is the most expensive mistake in pharmaceutical marketing."

Act II — The Process

Five stages.
Zero compromise.

Our methodology was built inside pharma, not imported from consumer branding. Every stage accounts for the regulatory reality your brand lives in.

Brand audit process with pharmaceutical marketing materials spread on a table

Stage 01

Brand Audit

72-point audit framework across 6 brand dimensions

01

Brand Audit

We dissect every existing touchpoint — packaging, digital, clinical materials, trade presence — against competitor landscapes and HCP perception data. You leave with a gap map no consultant has shown you before.

02

Naming & Positioning

03

Visual System

04

Regulatory Review

05

Launch Toolkit

Act III — The Proof

Results that appear
in the data.

Three engagements. Three categories. Measurable outcomes that justified the brand investment within the first fiscal year.

Before

Generic pharmaceutical packaging before Veralix brand redesign

After

Veralix oncology brand identity system after Prescribe redesign
Oncology — Biosimilar Launch

Veralix

The challenge: A mid-cap oncology company launching a biosimilar into a market dominated by the reference product's established brand equity. HCPs had zero reason to switch based on brand alone.

The outcome: Repositioned Veralix as "precision dosing made visible" — a brand built around the clinical workflow benefit, not the molecule. Formulary adoption reached 34% in Q1, exceeding forecast by 2.1×.

34%

Q1 formulary adoption

2.1×

Forecast exceeded

61%

Unaided recall at 90 days

Before

Generic biotech brand materials before Novalent identity redesign

After

Novalent CNS brand identity system after Prescribe redesign
CNS — Biotech Pre-FDA

Novalent

The challenge: A Series C biotech preparing for FDA approval needed an investor-facing identity system that could pivot to commercial without a rebrand. The science was validated; the brand was a PowerPoint template.

The outcome: Built a dual-purpose identity: rigorous enough for NDA submission materials, compelling enough for Series D roadshow. Raised $180M at a 40% premium to pre-brand valuation.

$180M

Series D raised

40%

Valuation premium

8 wks

Audit to full identity

Before

Fragmented hospital supply brand materials before Meridian merger rebrand

After

Meridian MedSupply unified brand identity after Prescribe post-merger rebrand
Hospital Supply — Post-Merger Rebrand

Meridian MedSupply

The challenge: Three regional hospital supply companies merged under private equity. Three logos, three color systems, three cultures — procurement directors couldn't tell who they were buying from.

The outcome: Unified identity across 2,400 SKUs in 14 weeks. New brand architecture reduced procurement confusion, contributing to a 22% increase in contract renewal rates in year one.

2,400

SKUs unified

14 wks

Full system delivery

+22%

Contract renewal lift

Start a brand
conversation.

We work with a small number of pharmaceutical companies at a time. If you're preparing a launch, navigating a merger, or building toward FDA approval — let's talk before the window closes.

We respond within one business day. No sales sequence — a real conversation.

The Pharma Brand Audit Framework

72 questions across 6 brand dimensions. Download free — work email required.

Who we work with

Mid-cap pharma

Generic & specialty launches

Biotech startups

Pre-FDA investor identity

Hospital supply

Post-merger rebrands

"Prescribe didn't just design our brand — they built the visual argument for why our molecule deserved to be prescribed first."

Dr. Sarah Chen, CMO — Veralix